RET and non-small cell lung carcinoma: RET inhibitors, selpercatinib and pralsetinib, are in phase III clinical trials and approved for the therapeutic use in individuals with metastatic RET fusion‐positive NSCLC by comparing them with standard first‐line therapy to observe its efficacy in RET‐positive NSCLC patients.142